Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Pseudomonas aeruginosa | Beta Lactamase | Starlite/ChEMBL | No references |
Homo sapiens | lysine (K)-specific demethylase 4A | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | beta lactamase | 0.0077 | 0.3336 | 0.5 |
Loa Loa (eye worm) | jmjC domain-containing protein | 0.0043 | 0.0592 | 0.1976 |
Schistosoma mansoni | jumonji domain containing protein | 0.0092 | 0.451 | 1 |
Plasmodium falciparum | phd finger protein, putative | 0.0035 | 0 | 0.5 |
Onchocerca volvulus | Alhambra homolog | 0.0035 | 0 | 0.5 |
Schistosoma mansoni | jumonji/arid domain-containing protein | 0.0043 | 0.0592 | 0.1313 |
Echinococcus multilocularis | jumonji domain containing protein | 0.0049 | 0.1103 | 0.1721 |
Mycobacterium ulcerans | class a beta-lactamase, BlaC | 0.016 | 1 | 1 |
Echinococcus multilocularis | lysine specific demethylase 5A | 0.0043 | 0.0592 | 0.0925 |
Toxoplasma gondii | PHD-finger domain-containing protein | 0.0035 | 0 | 0.5 |
Toxoplasma gondii | PHD-finger domain-containing protein | 0.0035 | 0 | 0.5 |
Brugia malayi | jmjC domain containing protein | 0.0115 | 0.6406 | 1 |
Mycobacterium leprae | PROBABLE CONSERVED LIPOPROTEIN LPQF | 0.0077 | 0.3336 | 0.5 |
Echinococcus multilocularis | Transcription factor, JmjC domain containing protein | 0.0115 | 0.6406 | 1 |
Loa Loa (eye worm) | jmjC domain-containing protein | 0.0073 | 0.2998 | 1 |
Plasmodium vivax | hypothetical protein, conserved | 0.0035 | 0 | 0.5 |
Echinococcus granulosus | Transcription factor JmjC domain containing protein | 0.0115 | 0.6406 | 1 |
Echinococcus granulosus | lysine specific demethylase 5A | 0.0043 | 0.0592 | 0.0925 |
Echinococcus granulosus | jumonji domain containing protein | 0.0049 | 0.1103 | 0.1721 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.2011 | 0.6709 |
Brugia malayi | jmjC domain containing protein | 0.0043 | 0.0592 | 0.0925 |
Giardia lamblia | PHD finger protein 15 | 0.0035 | 0 | 0.5 |
Schistosoma mansoni | jumonji/arid domain-containing protein | 0.0043 | 0.0592 | 0.1313 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 3.476 uM | PubChem BioAssay. FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify epi-absorbance assay artifacts. (Class of assay: confirmatory) | ChEMBL. | No reference |
IC50 (binding) | = 10.161 uM | PubChem BioAssay. Epi-absorbance-based dose response biochemical high throughput screening assay for selective inhibitors of VIM-2 metallo-beta-lactamase. (Class of assay: confirmatory) | ChEMBL. | No reference |
IC50 (binding) | > 59.64 uM | PubChem BioAssay. Epi-absorbance-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify inhibitors of TEM-1 serine-beta-lactamase. (Class of assay: confirmatory) | ChEMBL. | No reference |
IC50 (binding) | > 59.64 uM | PubChem BioAssay. FRET-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase. (Class of assay: confirmatory) | ChEMBL. | No reference |
IC50 (binding) | > 59.64 uM | PubChem BioAssay. Epi-absorbance-based counterscreen for selective VIM-2 inhibitors: dose response biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 17.7828 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.